Jorge L. Santana, MD
Director e Investigador Principal Proyecto ACTU
IUPR-CTU

Proyecto ACTU

Rev. por: SID, 10/SEP/2018

	PROTOCOLOS ABIERTOS A RECLUTAMIENTO	Criterios Inclusión Generales
1	**A5320:** Viral Hepatitis C Infection Long-term Cohort Study (V-HICS) *Non-SVR arms (Group A, coinfected and Group B, monoinfected) is open to accrual*.	➢ Diagnóstico VIH+ y HCV+, ≥ 18 años de edad ➢ Haber completado el tratamiento de HCV/DAA en los pasados 12 meses
2	**A5324:** A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV. Limited slots available	➢ Diagnóstico VIH+, ≥ 18 años de edad ➢ Carga Viral de VIH menor de 50 copias ➢ Estar tomando ART por al menos 12 meses antes de la entrada al estudio ➢ Diagnóstico de HAND
3	**REPRIEVE (A5332**): Randomized Trial to Prevent Vascular Events in HIV-Infected Patients.	➢ Diagnóstico VIH+, ≥40 a ≤75 años de edad ➢ Conteo CD4 ≥ 100 ➢ estar en ART por ≥ 180 días
4	**ARBO-001:** SUBSTUDY OF LABORATORY ANALYSIS OF IMMUNE REACTIONS TO ZIKA VIRUS AMONG INDIVIDUALS WITH PAST OR RECENT ZIKA VIRUS INFECTION. Few slots available.	➢ entre 18 y 65 años de edad ➢ Infección del virus de Zika coinfirmada
5	**A5345:** Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control during an Intensively Monitored Antiretroviral Pause (IMAP). **Sub-estudio A5347s**	➢ Diagnóstico VIH+, entre 18 y 70 años de edad. ➢ Conteo de CD4+ ≥200 cells/uL ➢ Carga Viral de VIH <20 copias/mL (Roche TaqMan v2.0) o <40 copias/mL (Abott).

Para más información: Daniel Casiano, Director Equipo de Comunidad
◆ daniel.casiano@upr.edu ◆ Tel. 787-767-9192, -9193, -9194, -9195 ◆ Fax 787-754-8002
P.O. Box 365067 San Juan, PR 00936-5067

Jorge L. Santana, MD
Director e Investigador Principal Proyecto ACTU
IUPR-CTU

Futuros Estudios:

Rev. por: SID, 10/SEP/2018

A5355: Phase I, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Modified Vaccinia Ankara (MVA)-based anti-CMV Vaccine (Triplex®), in Human Immunodeficiency Virus (HIV)-1 and CMV Co-Infected Adults who are on Potent Combination ART with Conserved Immune Function

A5357: A Proof-of-Concept Study of Long-Acting Cabotegravir Plus VRC01LS to Maintain Viral Suppression in HIV-1-infected Adults.

A5359: Long-Acting Antiretroviral Therapy in Non-adherent HIV-Infected Individuals

A5360: Minimal vs. Standard Monitoring for the Delivery of All Oral Ribavirin-Free Pan Genotypic Directly Acting Antivirals (DAA) to Chronically Infected Treatment Naïve HCV Populations Globally: MINMON Study.

A5363: A Multicenter, Prospective, Double-Blind, Randomized Placebo-Controlled Study to Evaluate the Effects of Cenicriviroc on Arterial Inflammation in People Living with HIV.

A5367: A Phase I Randomized Study of the Safety And Ability to Prevent Viral Relapse of Vedolizumab In Participants With Treated Acute HIV Infection Who Undergo Antiretroviral Treatment Interruption.

A5368: "Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-1 Antibody in HBV Infected Participants on Suppressive Antiviral Therapy: A Phase I/II Ascending Multiple Dose Study," i

A5369: HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) as Therapeutic Vaccination in HIV-Infected Persons with Viral Suppression on Antiretroviral Therapy

A5370: Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-1 Antibody (REGN2810) in HIV-1-infected Participants on Suppressive cART: A Phase II, Double-blind, Placebo-controlled, Ascending Multiple Dose Study

A5371: A Randomized, Open-Label Pilot Study of Potential Treatment Strategies for Non-alcoholic Fatty Liver Disease (NAFLD), a Metabolic Syndrome with Insulin Resistance, Increased Hepatic Lipids, and Increased Cardiovascular Disease Risk.

A5375: Optimizing Levonorgestrel Emergency Contraception in Combination with Antiretroviral Therapy and Anti-Tuberculosis Therapy: A Pharmacokinetic Study

A5376: Pharmacokinetic Interactions of Etonogestrel Subdermal Implants (ENG) with Rilpivirine (RPV) Combined with Tenofovir Alafenamide (TAF) and Emtricitabine (FTC)

A5377: A Phase I, First-in-human, Ascending Dose Study of SAR441236, a Tri-specific Broadly Neutralizing Antibody in HIV-infected Participants

A5378: A Phase 1, Single Dose Study of the Safety and Virologic Effect of an HIV-1 Specific Broadly Neutralizing Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS) or VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously to HIV-Infected Adults.

A5379: HBV Vaccination in HIV-Infected Persons: Randomized, Controlled Trials of HEPLISAV-B vs. Engerix-B.

A5380: Glecaprevir/pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C)

ARBO-004 Zika virus sero-prevalence and assessment of the Dual Path Platform® Zika IgM assay to detect recent or current Zika virus infection

Para más información: Daniel Casiano, Director Equipo de Comunidad
◆ daniel.casiano@upr.edu ◆ Tel. 787-767-9192, -9193, -9194, -9195 ◆ Fax 787-754-8002
P.O. Box 365067 San Juan, PR 00936-5067